Table 3.

Attitudes towards the regulation of specific RGS practices

From 1 (fully opposing) to 10 (fully supporting)		Israel (n = 18)		Spain (n = 18)
From 1 (fully opposing) to 10 (fully supporting)		Mean	SD	Mean	SD
Strong support
1. PGT-M for severe monogenic disorders for early-onset and of high levels of penetrance with no simple cure	Allow	9.6	0.62	9.3	2.20
	Fund	9.5	0.64	8.9	2.30
2. PGT-M for severe monogenic disorders for medium-late onset and of high levels of penetrance with no simple cure	Allow	9.4	0.81	8.9	2.19
	Fund	9.2	0.94	8.5	2.35
3. PGT-M for severe monogenic disorders for medium-late onset and of medium levels of penetrance with no simple cure	Allow	7.5	2.22	8.6	2.43
	Fund	6.9	2.29	8.1	2.60
Mild support
4. GGM (CRISPR/Cas) for severe monogenic disorders for early-onset and of high levels of penetrance with no simple cure in case PGT did not provide a solution	Allow	7.5	2.29	6.4	3.39
	Fund	6.5	2.79	4.8	3.51
5. PGT-A for detection of chromosomal abnormalities, in order to increase the prospects of an IVF treatment	Allow	6.9	2.79	6.2	3.29
	Fund	5.7	2.97	4.3	3.24
6. PGT for multifactorial diseases (cancerous/metabolic/cardiovascular/neurological) for medium-late onset and of medium levels of penetrance	Allow	6.4	2.60	6.0	3.28
	Fund	5.2	2.34	4.3	2.66
7. PGT for whole-exome screening	Allow	3.8	2.29	4.3	3.15
7. PGT for whole-exome screening	Fund	2.6	2.22	3.1	2.82
Disapproval
8. PGT for sex selection	Allow	2.1	1.88	3.7	3.37
8. PGT for sex selection	Fund	1.8	1.51	1.4	1.42
9. PGT for cognitive characteristics selection	Allow	1.3	1.19	1.5	1.29
9. PGT for cognitive characteristics selection	Fund	1.4	1.22	1.3	0.96
10. PGT for physical traits selection	Allow	1.3	1.19	1.3	0.97
10. PGT for physical traits selection	Fund	1.4	1.22	1.3	0.96